Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
NervGen Pharma Corp. (NGEN) had Return on Tangible Equity of -805.78% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-31.64M |
|
-- |
|
-- |
|
$16.67M |
|
$-16.67M |
|
$-14.98M |
|
$-31.64M |
|
$-31.64M |
|
$-31.64M |
|
$-31.64M |
|
$-31.64M |
|
$-31.64M |
|
$-16.67M |
|
$-16.63M |
|
72.33M |
|
72.33M |
|
$-0.44 |
|
$-0.44 |
|
| Balance Sheet Financials | |
$16.32M |
|
-- |
|
$0.29M |
|
$16.61M |
|
$12.39M |
|
-- |
|
-- |
|
$12.39M |
|
$4.22M |
|
$3.93M |
|
$4.22M |
|
79.65M |
|
| Cash Flow Statement Financials | |
$-13.96M |
|
$0.07M |
|
$17.01M |
|
$12.36M |
|
$15.80M |
|
$3.44M |
|
$2.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.32 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-13.96M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-749.87% |
|
|
Return on Tangible Equity |
-805.78% |
-190.50% |
|
-749.86% |
|
$0.05 |
|
$-0.19 |
|
$-0.19 |
|